T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone781-761-4646
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.50 million
Profitability
Miscellaneous
Employees153
Next Earnings DateN/A
OptionableOptionable
T2 Biosystems (NASDAQ:TTOO) Frequently Asked Questions
What is T2 Biosystems' stock symbol?
T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO."
How were T2 Biosystems' earnings last quarter?
T2 Biosystems Inc (NASDAQ:TTOO) announced its earnings results on Tuesday, July, 30th. The medical equipment provider reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.03. The medical equipment provider had revenue of $1.80 million for the quarter, compared to analysts' expectations of $1.95 million. T2 Biosystems had a negative net margin of 722.70% and a negative return on equity of 1,263.94%. The company's revenue for the quarter was down 53.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.32) earnings per share. View T2 Biosystems' Earnings History.
What price target have analysts set for TTOO?
8 Wall Street analysts have issued 12-month price targets for T2 Biosystems' shares. Their forecasts range from $0.40 to $10.00. On average, they anticipate T2 Biosystems' stock price to reach $5.55 in the next twelve months. This suggests a possible upside of 234.3% from the stock's current price. View Analyst Price Targets for T2 Biosystems.
What is the consensus analysts' recommendation for T2 Biosystems?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for T2 Biosystems.
What are Wall Street analysts saying about T2 Biosystems stock?
Here are some recent quotes from research analysts about T2 Biosystems stock:
- 1. According to Zacks Investment Research, "T2 Biosystems, Inc. is an in vitro diagnostics company. It has developed a technology platform that is designed to offer a rapid, sensitive and simple alternative to existing diagnostic methodologies. The Company uses its T2 Magnetic Resonance platform, or T2MR, that enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets. It operates primarily in the United States. T2 Biosystems, Inc. is headquartered in Lexington, Massachusetts. " (11/15/2019)
- 2. HC Wainwright analysts commented, "We do not currently have a price target on TTOO shares. Risks include, but are not limited to: (1) failure of to achieve commercial success due to market size, penetration rate, and/or competition; (2) failure to secure regulatory approval for T2Lyme; and (3) potential dilution risk." (8/7/2019)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our OW rating and 12-month PT of $10 on shares of TTOO. T2 reported 1Q19 product revenue of $1.3MM (+25% y/y), beating our estimate and VisibleAlpha consensus estimates by $0.3MM. Total 1Q19 revenue beat FactSet consensus and the top-end of management’s 1Q19 revenue guide. T2 closed on 11 T2Dx contracts during the quarter, above guidance of 8-10. Management reiterated 2019 revenue guidance and provided 2Q product revenue expectations of +35% growth at the midpoint. We are positive on the momentum of T2’s start to the year, and we continue to think that 2H19 will be pivotal for consumable revenue acceleration and consequently the shares." (5/3/2019)
Has T2 Biosystems been receiving favorable news coverage?
Media stories about TTOO stock have been trending very negative recently, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. T2 Biosystems earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for T2 Biosystems.
Are investors shorting T2 Biosystems?
T2 Biosystems saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 4,730,000 shares, an increase of 11.3% from the September 30th total of 4,250,000 shares. Based on an average trading volume of 1,303,400 shares, the short-interest ratio is currently 3.6 days. Approximately 13.3% of the company's stock are short sold. View T2 Biosystems' Current Options Chain.
Who are some of T2 Biosystems' key competitors?
Some companies that are related to T2 Biosystems include Apyx Medical (APYX), Iradimed (IRMD), Accuray (ARAY), SeaSpine (SPNE), Inovio Pharmaceuticals (INO), Vapotherm (VAPO), Soliton (SOLY), Repro Med Systems (KRMD), RenovaCare (RCAR), Repro-Med Systems (REPR), Cytosorbents (CTSO), iCAD (ICAD), BRAINSWAY LTD/S (BWAY), Spectral Medical (EDTXF) and STRATA Skin Sciences (SSKN).
What other stocks do shareholders of T2 Biosystems own?
Who are T2 Biosystems' key executives?
T2 Biosystems' management team includes the folowing people:
- Mr. John P. McDonough, CEO, Pres & Director (Age 59)
- Prof. Michael J. Cima, Co-Founder & Director (Age 59)
- Dr. Thomas J. Lowery Jr., Chief Scientific Officer (Age 40)
- Dr. Tyler E. Jacks, Co-Founder (Age 58)
- Mr. Lee Josephson, Co-Founder & Member of Scientific Advisory Board
Who are T2 Biosystems' major shareholders?
T2 Biosystems' stock is owned by many different of institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (0.75%), Focused Wealth Management Inc (0.09%), Cable Hill Partners LLC (0.07%), Ironwood Financial llc (0.04%), Founders Capital Management (0.04%) and Creative Planning (0.04%). Company insiders that own T2 Biosystems stock include Alec Barclay, David B Elsbree, John Mcdonough, Michael J Cima, Michael Terrence Gibbs, Stanley Lapidus and Thomas J Lowery. View Institutional Ownership Trends for T2 Biosystems.
Which institutional investors are buying T2 Biosystems stock?
TTOO stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Creative Planning, Commonwealth Equity Services LLC, Ironwood Financial llc, Founders Capital Management, Focused Wealth Management Inc and Cable Hill Partners LLC. View Insider Buying and Selling for T2 Biosystems.
How do I buy shares of T2 Biosystems?
Shares of TTOO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is T2 Biosystems' stock price today?
One share of TTOO stock can currently be purchased for approximately $1.66.
How big of a company is T2 Biosystems?
T2 Biosystems has a market capitalization of $73.94 million and generates $10.50 million in revenue each year. The medical equipment provider earns $-51,150,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. T2 Biosystems employs 153 workers across the globe.View Additional Information About T2 Biosystems.
What is T2 Biosystems' official website?
How can I contact T2 Biosystems?
T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The medical equipment provider can be reached via phone at 781-761-4646 or via email at [email protected]
MarketBeat Community Rating for T2 Biosystems (NASDAQ TTOO)
MarketBeat's community ratings are surveys of what our community members think about T2 Biosystems and other stocks. Vote "Outperform" if you believe TTOO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTOO will underperform the S&P 500 over the long term. You may vote once every thirty days.
